Protein biomarker for lymphangioleiomyomatosis and application thereof

• Main Authors: YUE JUNQING, ZHANG SHENGDING, BAI WENXUE, XIE MIN
• Format: Patent
• Language: Chinese; English
• Published: 15.07.2022
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

The invention discloses a protein biomarker for lymphangioleiomyomatosis and application thereof, and belongs to the technical field of immunodetection. The method specifically comprises the step of detecting the expression quantity of any one or a combination of more than two of ferritin, beta2 microglobulin or transferrin in the plasma of a subject, and a test finds that the contents of ferritin, beta2 microglobulin and transferrin in the plasma have significant difference between a patient with lymphangioleiomyomatosis and a healthy control group, so that the content of the ferritin, beta2 microglobulin and transferrin in the plasma has significant difference between the patient with lymphangioleiomyomatosis and the healthy control group. Any one or a combination of more than two of ferritin, beta2 microglobulin or transferrin can be used as a marker for auxiliary diagnosis of LAM, and positive significance is provided for assisting clinical diagnosis and treatment. 本发明公开了一种淋巴管平滑肌瘤病的蛋白质生物标志物及应用，属于免疫检测技术领域。